Welcome to our dedicated page for Sol Gel Tech SEC filings (Ticker: SLGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sol-Gel Technologies Ltd. (NASDAQ: SLGL) files reports with the U.S. Securities and Exchange Commission as a foreign private issuer, primarily through annual reports on Form 20-F and current reports on Form 6-K. These SEC filings document the company’s activities as a dermatology-focused developer of topical drug products such as TWYNEO and EPSOLAY and pipeline candidates including SGT-610 and SGT-210.
On this page, you can review Sol-Gel’s Form 6-K submissions that furnish press releases and, in some cases, unaudited condensed consolidated financial statements for specific periods. These filings cover topics such as quarterly and semi-annual financial results, updates on the Phase 3 clinical trial of SGT-610 for Gorlin syndrome, developments in the Phase 1b study of SGT-210 in Darier disease, licensing and product purchase agreements for EPSOLAY and TWYNEO, and corporate actions like the 10-for-1 reverse share split and the transfer of the company’s listing to the Nasdaq Capital Market.
Sol-Gel’s filings also include proxy materials for annual shareholder meetings, auditor appointments, board and executive approvals and other governance matters. Certain press releases attached as exhibits to Form 6-K are expressly incorporated by reference into the company’s registration statements on Form S-8 and Form F-3, as noted in the filings. For investors analyzing SLGL, the 20-F annual report and accompanying risk factor discussions provide additional context on clinical, regulatory, financial and market risks associated with the company’s dermatology portfolio and rare disease programs.
Stock Titan’s SEC filings page for SLGL presents these documents with real-time updates from EDGAR and AI-powered summaries that highlight key points in lengthy disclosures. This helps readers quickly understand Sol-Gel’s financial position, clinical trial status, licensing arrangements and corporate actions without manually parsing every line of each 6-K or 20-F filing.
Sol-Gel Technologies Ltd. filed Post-Effective Amendment No. 4 converting its prior Form F-1 registration into a Form F-3 and incorporating its audited financial results for the fiscal year ended December 31, 2025. The amendment does not register any additional securities.
Offering details: the prospectus covers resale by selling shareholders of up to 656,000 ordinary shares (par value NIS 1.0), comprised of 256,000 Investor Warrant Shares, 200,000 Affiliate Shares and 200,000 Affiliate Warrant Shares. Ordinary shares outstanding were 2,809,879 as of March 18, 2026 and would be 3,265,879 assuming issuance of the referenced warrant shares. The company will not receive proceeds from resale transactions, but may receive up to $26,676,000 assuming full cash exercise of the warrants, which the prospectus states would be used for general corporate purposes.
Sol-Gel Technologies Ltd. files its annual report on Form 20-F, detailing a specialty dermatology business that remains deeply loss-making and high risk. The company reported net losses of $27.2M in 2023, $10.6M in 2024 and $6.1M in 2025, leading to an accumulated deficit of $237M as of December 31, 2025.
The auditors included a going-concern explanatory paragraph, reflecting substantial doubt about Sol-Gel’s ability to continue operating without additional capital. Operations have been funded mainly through equity offerings and loans from the controlling shareholder, and management expects significant further losses as it develops SGT-610 and other candidates.
Sol-Gel has FDA-approved products Twyneo and Epsolay but sold its U.S. rights to Mayne in April 2025 for up to $16M in upfront and milestone payments, and relies on license partners in Canada, China and other territories. All current pipeline products remain in development and face extensive clinical, regulatory, funding and commercialization risks.
Sol-Gel Technologies Ltd. executive Yosef Itzik, the Chief Operating Officer, reported his initial beneficial ownership of stock options on Ordinary Shares. He holds options over 2,031 Ordinary Shares at an exercise price of 100.0000 per share, expiring on March 29, 2032.
He also holds options over 566 Ordinary Shares at an exercise price of 56.0000 per share, expiring on March 9, 2033, and 499 Ordinary Shares at an exercise price of 8.9600 per share, expiring on February 18, 2035. The footnotes describe vesting schedules where 25% of each grant vests on a specified initial date, with the remaining portion vesting in equal quarterly installments, subject to his continued service.
Sol-Gel Technologies Ltd. Chief Financial Officer Eyal Ben-Or filed an initial ownership report showing direct holdings of 1,000 Ordinary Shares and several stock option awards. These include options over 7,500 Ordinary Shares at an exercise price of 69.5000 per share, expiring on January 19, 2036. Footnotes state that some options are fully vested, while others vest 25% on specified dates and then in equal quarterly installments over three years, subject to his continued service.
Sol-Gel Technologies Ltd. director Gottfried Ran filed an initial Form 3 showing his equity stake in the company. He directly holds 1,550 Ordinary Shares and two stock option grants over 4,500 and 7,500 Ordinary Shares, with exercise prices of 100.2000 and 12.0000, expiring on February 2, 2031 and January 9, 2034, respectively.
One option is fully vested, while the other vested 33.33% on February 28, 2025 and continues to vest in equal quarterly installments over two years, subject to his continued service as a director.
Sol-Gel Technologies Ltd. director Sharon Kochan reported existing derivative holdings in an initial ownership statement. The filing lists a stock option to buy 7,500 Ordinary Shares at an exercise price of $12.0000 per share, expiring on January 9, 2034.
The option vested as to 33.33% of the underlying Ordinary Shares on February 28, 2025 and is scheduled to vest in equal quarterly installments over the following two years, conditioned on continued service as a director. All 7,500 underlying shares are reported as directly held through this option position.
Sol-Gel Technologies Ltd. director Yanai Yuval has reported initial beneficial ownership of a stock option to buy Ordinary Shares. The option covers 7,500 underlying Ordinary Shares at an exercise price of $12.0000 per share and expires on January 9, 2034.
According to the vesting terms, 33.33% of the option vested on February 28, 2025, with the remaining Ordinary Shares vesting in equal quarterly installments over the following two years, subject to his continued service as a director.
Sol-Gel Technologies Ltd. director Hanna Lerman reports holding a fully vested stock option to buy 2,031 ordinary shares at an exercise price of 55.6600. The option relates to ordinary shares with NIS 1.00 par value per share and expires on 2027-07-13.
Sol-Gel Technologies Ltd. director Arkin Itai Gidon filed an initial statement of beneficial ownership on Form 3. The filing lists him as a director of the company but does not report any buy, sell, or other share transactions in this submission.
Sol-Gel Technologies Ltd. executive Michael Glezin, the Chief Business Officer, has filed an initial ownership report showing his holdings in the company’s ordinary shares and stock options. This Form 3 does not reflect new trades but discloses his current equity position.
Glezin directly holds 1,500 Ordinary Shares and several stock option awards over ordinary shares. These options cover 2,500 shares at an exercise price of $49.80 expiring on November 2, 2032, 5,000 shares at $8.96 expiring on February 18, 2035, and 7,500 shares at $69.50 expiring on January 19, 2036. Footnotes state that each option vests 25% on a specified initial date, with the remaining 75% vesting in equal quarterly installments over three years, subject to his continued service.